Prosecution Insights
Last updated: April 19, 2026

Lantern Pharma Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18500032 Method for Treating Blood Cancers BARSKY, JARED 1628 Non-Final OA Nov 01, 2023
18238512 ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME BONAPARTE, AMY C 1692 Non-Final OA Aug 27, 2023
18349256 TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE BRAUN, MADELINE E 1624 Non-Final OA Jul 10, 2023
17998117 Method For Treating Pancreatic Cancer MAHLUM, JONATHAN DAVIS 1625 Non-Final OA Nov 07, 2022
17995904 Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer WILSON, JERICA KATLYNN 1621 Final Rejection Oct 10, 2022
17230821 Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers VISONE, THOMAS J 1672 Final Rejection Apr 14, 2021

Managing Lantern Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month